Crossmark

Testing the anti-osteoclastic function of biologic DMARDs

Crossref DOI link: https://doi.org/10.1038/s41584-018-0046-0

Published Online: 2018-07-11

Published Print: 2018-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cutolo, Maurizio

Sulli, Alberto
License Information

Text and Data Mining valid from 2018-07-11
More Information

Article History

First Online: 11 July 2018

Competing interests

: M.C. declares he has received university research funds from Actelion Pharmaceuticals Ltd, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, and Horizon Pharma. A.S. declares no competing interests.